ArticleBMC gastroenterology2026
Glasgow prognostic score as a predictor of adjuvant nivolumab efficacy in esophageal squamous cell carcinoma.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAdjuvant nivolumab is standard for locally advanced esophageal cancer patients without pathological complete response after neoadjuvant chemoradiotherapy, and this study evaluated its efficacy and the predictive value of the Glasgow Prognostic Score on survival.
methodsWe retrospectively analyzed 33 patients diagnosed with stage II-III esophageal squamous cell carcinoma (ESCC) who were followed at our center between January 2020 and January 2025. These patients had undergone neoadjuvant chemoradiotherapy followed by R0 resection yet exhibited residual disease (ypT1-4 or ypN+). The relationship between disease-free survival (DFS) and overall survival (OS) and GPS (0,1,2) was analyzed.
resultsOur study shows that adjuvant nivolumab is effective in ESCC, with superior responses in patients with low Glasgow Prognostic Score and markedly reduced benefit in those with high GPS. Mean DFS was 43.2 months in GPS 0 patients (median not reached), compared with median DFS of 12 and 5 months in the GPS 1 and GPS 2 groups, respectively. Mean OS in the GPS 0 group was 49.5 months (median not reached), while median OS decreased to 27 months in GPS 1 and 10 months in GPS 2 patients.
conclusionAdjuvant nivolumab improves survival in locally advanced ESCC with residual disease. Lower Glasgow Prognostic Score is associated with improved DFS and OS, underscoring the role of systemic inflammation in immunotherapy response. GPS may be a simple and cost-effective predictive biomarker for adjuvant immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.